France The latest issue of Healthcare & Life Sciences Review France follows on from our March 2019 report and takes a closer look at the wider French life sciences value chain and the spirit of innovation and reform sweeping the nation. A reform-minded and business-oriented administration under President Emmanuel Macron…
Korea One of the indisputable economic success stories of the last half-century, South Korea now stands as the world’s 11th largest economy, with a reputation for industrial excellence and innovation. As the Korean state shifts its focus towards healthcare and the life sciences and Korean firms begin to internationalize with greater…
Egypt Ashraf Osman, president and CEO of AUG Pharma, explains how his company has become one of Egypt’s Top 30 pharmaceutical companies in less than four years of manufacturing, gives an insight into the branding strategy of an industry newcomer, and outlines the company’s export strategy. In 2018 alone we…
Egypt Dr Maged George, chairman of the Egyptian Export Council of Medical Industries, highlights the obstacles that the Egyptian pharmaceutical industry is facing in the wake of the currency devaluation both locally and abroad. He also gives insights into Egypt’s new consolidated approach of targeting other African countries for exports, uniting…
Egypt Ahmed Zaghloul, CEO of October Pharma, stresses the need for better infrastructure for biosimilars in Egypt to stay competitive on a global level. He also highlights October Pharma’s ambitious export strategy, targeting markets in the Gulf Region and South East Asia. Production costs are rising, and pricing pressures continue,…
Portugal Joana Silveira Botelho of Cuatrecasas argues for the need for an EU-wide regulatory update on the advertising of pharmaceutical products online, given current rules do not take into account the spread and influence of social media today. Today’s internet is so much more than a company’s website It is…
China Click here to register and download PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: China. From the world’s ninth largest pharma market in 2007 to its second-biggest merely 12 years later, China and its growth story are impossible to ignore. China now accounts for a significant share of revenues…
France France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition. With Brexit uncertainties across the channel and populist tendencies souring the prospects of some of its neighbours, France – under…
Turkey Turkey – home to an 80 million-strong population, a substantial pharmaceuticals market and a universal healthcare system that is the envy of its neighbours – stands as one of the most promising healthcare and life science investment destinations in its region. Topics covered in this report range from the successes…
Algeria Click here to download the Healthcare & Life Sciences Review Algeria 2019 report. Algeria, Africa’s largest country by area, stands as a promising investment destination for the global life sciences industry, with a sizeable local market and a growing number of multinationals choosing to base their regional operations out…
Turkey Imports and exports in Turkish pharma between 2010 and 2017. Pharmaceutical exports grew to a total of USD 898 million in 2017. These charts show both the volume and value of imported and locally-produced drugs in the Turkish pharma market between 2010 and 2017. TL 13.33 billion (USD 2.57…
Turkey Armağan Vurdu, general secretary of the Istanbul Minerals and Metals Exporters Association (IMMIB) highlights the strategic importance of the chemical and pharmaceutical sectors in Turkey’s exports. He underscores pharma’s role in Turkey’s ‘Vision 2023’ and explains how IMMIB is helping the sector increase its export potential. With our 29…
See our Cookie Privacy Policy Here